Talecris announces launch of PROLASTIN-C in Canada

Talecris Biotherapeutics (Nasdaq: TLCR) announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years.  PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min. 

PROLASTIN-C has replaced PROLASTIN in Canada. Both products are indicated for chronic augmentation and maintenance therapy in adults who have emphysema due to a genetic condition known as alpha1-antitrypsin (AAT) deficiency. The active protein in PROLASTIN-C increases or "augments" protein levels in AAT-deficient patients.

"Talecris research and development scientists continually strive to enhance the overall quality of our products by incorporating the latest advances in technology," said Joel Abelson, Senior Vice President & General Manager, Portfolio Management & International Business. "PROLASTIN-C is an example of our commitment to supporting patients who use protein therapies to treat their rare and life-threatening conditions."

PROLASTIN-C contains the same active ingredient as PROLASTIN. Clinical studies demonstrated that the products are equally effective at raising alpha1 levels, and that PROLASTIN-C has an adverse event profile consistent with that of PROLASTIN.  (http://www.biomedcentral.com/1472-6904/10/13

Patients in Canada who were receiving PROLASTIN were successfully transitioned to PROLASTIN-C during September and October 2010. Information about this transition is available through PROLASTIN DIRECT™ CANADA at 1-877-3ALPHA1 and through pharmacies that assist physicians and their patients who were receiving PROLASTIN therapy.  

A similar transition was completed in the U.S. earlier this year. Information about the U.S. transition can be obtained through PROLASTIN DIRECT® at 800-305-7881, the product's exclusive distribution program. Information about the transition to PROLASTIN-C in other countries will be provided as regulatory approvals are granted.